These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8251767)

  • 21. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
    Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
    J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
    Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
    Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
    Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
    Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
    Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
    Bone; 1986; 7(4):247-53. PubMed ID: 3768203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1988 Jan; 118(3):77-81. PubMed ID: 3344411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
    Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV
    Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
    Davis JR; Heath DA
    Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibandronate in oncology.
    Burckhardt P
    Cancer; 1997 Oct; 80(8 Suppl):1696-8. PubMed ID: 9362439
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
    Rizzoli R; Buchs B; Bonjour JP
    Int J Cancer; 1992 Mar; 50(5):706-12. PubMed ID: 1531972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ; Borkowski A; Cleeren A; Bijvoet OL
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
    J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ
    Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.